149281-19-6
| 中文名称 | 149281-19-6 |
|---|---|
| 中文同义词 | 化合物 T10780;化合物 CGP-53153 |
| 英文名称 | CGP-53153 |
| 英文同义词 | CGP-53153;1H-Indeno[5,4-f]quinoline-7-carboxamide, N-(1-cyano-1-methylethyl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- |
| CAS号 | 149281-19-6 |
| 分子式 | C23H33N3O2 |
| 分子量 | 383.52702 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 149281-19-6.mol |
| 结构式 |  |
149281-19-6 性质
| 沸点 | 627.0±55.0 °C(Predicted) |
|---|---|
| 密度 | 1.118±0.06 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | 溶于二甲基亚砜 |
| 酸度系数(pKa) | 12.88±0.60(Predicted) |
IC50: 36 nM (rat 5 alpha reductase), 262 nM (human 5 alpha reductase)
CGP-53153 competitively inhibits rat microsomal 5 alpha reductase from prostate with an IC 50 of 36 nM compared to the reference compound finasteride (IC 50 =11 nM). CGP 53153 is approximately one order of magnitude more potent in inhibiting rat compared to human 5 alpha reductase, with IC 50 values of 36 and 262 nM, respectively
CGP-53153 can significantly reduce T-propionate-mediated prostate growth at oral doses of 0.01 mg/kg. CGP-53153 significantly reduces prostate weight at 3 and 10 mg/kg by 31% and 37%, respectively. Treatment for 12 weeks with both CGP-53153 reduces prostate volume by more than 70% in individual dogs. Neither body weight nor the weight of any organ tested is affected by CGP-53153.